HOME
WHO WE ARE
WHAT WE DO
OUR TECHNOLOGY
PIPELINE
NEWS
CONTACT
Menu

EpyGenix Launches Phase II Trial for EPX-100

Sep 16, 2020/in News /by 3mediaweb

Read Full News Article Here:

https://www.dravetfoundation.org/2020-epygenix-launches-phaseii-trial-for-epx-100-9-04-20/

Share this entry

https://www.epygenix.com/wp-content/uploads/logo-new-light-R.1.png 0 0 3mediaweb https://www.epygenix.com/wp-content/uploads/logo-new-light-R.1.png 3mediaweb2020-09-16 14:26:052020-09-16 14:26:05EpyGenix Launches Phase II Trial for EPX-100

About Epygenix

Epygenix Therapeutics, Inc. is developing precision medicine for rare and catastrophic forms of genetic epilepsy, such as Dravet Syndrome, Lennox-Gastaut Syndrome, Infantile Spasm, and Otahara syndrome.

How To Find Us

Epygenix Therapeutics
140 E. Ridgewood Ave.
Suite 415, South Tower
Paramus, NJ 07652

Phone: 1 (201) 940-7377
Fax: 1 (201) 940-7218
info@epygenix.com

Latest News

Epygenix Therapeutics Initiates Phase 2 Study for Dravet Syndrome With EPX-100
EpyGenix Launches Phase II Trial for EPX-100
Epygenix Therapeutics Successfully Completes EPX-100 Phase I, Placebo-Controlled, Double-Blind, 2-Period Study and Ready to Phase 2 Studies
Epygenix Therapeutics Receives IND Approval of EPX-100 for the Treatment of Dravet Syndrome

Epygenix Therapeutics Successfully Completes EPX-100 Phase I, Placebo-Controlled,... Epygenix Therapeutics Initiates Phase 2 Study for Dravet Syndrome With EPX-...

Scroll to top